Chemocentryx reported $77.2M in Cash and Equivalent for its second fiscal quarter of 2021.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Cash And Equivalent Change
Alexion Pharmaceuticals ALXN:US $ 3429.6M 465.1M
Alnylam Pharmaceuticals ALNY:US $ 745.77M 366.22M
Amgen AMGN:US $ 6630M 518M
AstraZeneca AZN:LN 15567M 7931M
Bayer BAYN:GR € 3389M 2161M
Biogen BIIB:US $ 1742M 524.5M
Biomarin Pharmaceutical BMRN:US $ 641.53M 25.78M
Bristol Myers Squibb BMY:US $ 11024M 42M
Chemocentryx CCXI:US $ 77.2M 8.66M
GlaxoSmithKline GSK:LN 3503M 1254M
Glaxosmithkline GSK:US $ 3503M 1254M
Macrogenics MGNX:US $ 188.97M 29.53M
Mirati Therapeutics MRTX:US $ 258.99M 35.9M
Novartis NOVN:VX SF 5117M 1316M
Omeros OMER:US $ 12.7M 3.67M
Sarepta Therapeutics SRPT:US $ 1697.28M 215.44M
Takeda 4502:JP Y 654920M 311302M
Teva Pharmaceutical TEVA:IT 2.44B 693M
YTE INCY:US $ 1797.58M 127.61M